Clinical and hematologic parameters in 3 patients pre-transplant and postBMT failure
| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Sex/age* | M/18 | F/13 | M/5 |
| Disease | β°-thalassemia | β°-thalassemia | Sickle cell anemia |
| Follow-up after BMT (mo) | + 67 | + 55 | + 19 |
| Pre-BMT Hb (gr/dL) | 8.3-9.0 | 7.0-8.1 | 7.0-7.4 |
| Post-BMT Hb (gr/dL) | 11.8-13 | 10.2-10.55 | 11.4-12.3 |
| Pre-BMT HbF level (%) | 73 | 24 | 19.3 |
| Post-BMT HbF level (%) | 99.8 | 99.8 | 49.6 |
| Pre-BMT reticulocytes (%) | 4.07 | 4.09 | 10.1 |
| Post-BMT reticulocytes (%) | 6.57 | 7.95 | 3.15 |
| Pre-BMT circulating erythroblasts† (% of total nucleated cells) | 88 | 83 | 0 |
| Post-BMT circulating erythroblasts (% of total nucleated cells) | 58 | 60 | 0 |
| Pre-PMT HPLC‡ | α/non α: 2.47; %β: 0 | α/non α: 2.43; %β: 0 | α/non α: 1,1; %β: 100 β S |
| Post-BMT HPLC | α/non α: 0.97; %β: 0 | α/non α: 1.20; %β: 0 | α/non α: 1.16; β: 100 β S |
| Pre-BMT bone marrow biopsy | marked erythroid hyperplasia | marked erythroid hyperplasia | marked erythroid hyperplasia |
| Post-BMT bone marrow biopsy | mild erythroid hyperplasia | mild erythroid hyperplasia | normoblastic erythropoiesis |
| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Sex/age* | M/18 | F/13 | M/5 |
| Disease | β°-thalassemia | β°-thalassemia | Sickle cell anemia |
| Follow-up after BMT (mo) | + 67 | + 55 | + 19 |
| Pre-BMT Hb (gr/dL) | 8.3-9.0 | 7.0-8.1 | 7.0-7.4 |
| Post-BMT Hb (gr/dL) | 11.8-13 | 10.2-10.55 | 11.4-12.3 |
| Pre-BMT HbF level (%) | 73 | 24 | 19.3 |
| Post-BMT HbF level (%) | 99.8 | 99.8 | 49.6 |
| Pre-BMT reticulocytes (%) | 4.07 | 4.09 | 10.1 |
| Post-BMT reticulocytes (%) | 6.57 | 7.95 | 3.15 |
| Pre-BMT circulating erythroblasts† (% of total nucleated cells) | 88 | 83 | 0 |
| Post-BMT circulating erythroblasts (% of total nucleated cells) | 58 | 60 | 0 |
| Pre-PMT HPLC‡ | α/non α: 2.47; %β: 0 | α/non α: 2.43; %β: 0 | α/non α: 1,1; %β: 100 β S |
| Post-BMT HPLC | α/non α: 0.97; %β: 0 | α/non α: 1.20; %β: 0 | α/non α: 1.16; β: 100 β S |
| Pre-BMT bone marrow biopsy | marked erythroid hyperplasia | marked erythroid hyperplasia | marked erythroid hyperplasia |
| Post-BMT bone marrow biopsy | mild erythroid hyperplasia | mild erythroid hyperplasia | normoblastic erythropoiesis |